Wegovy vs Trulicity Real-World Evidence Comparison

What Are Wegovy and Trulicity, and How Do They Differ?

Wegovy and Trulicity are both once-weekly injectable GLP-1 receptor agonists, but they were developed for separate clinical problems. Wegovy delivers semaglutide at 2.4 mg. Trulicity delivers dulaglutide at doses between 0.75 mg and 4.5 mg. The molecular structures differ enough that their potency, receptor binding duration, and weight-loss outcomes diverge considerably.

Mechanism of Action

Both drugs bind to the GLP-1 receptor, which slows gastric emptying, suppresses appetite, and stimulates glucose-dependent insulin secretion. Semaglutide, however, has a longer half-life of approximately seven days and achieves more complete receptor occupancy at the doses used in Wegovy, which likely explains the larger weight-loss signal. Dulaglutide's half-life is about five days. Neither drug requires dose adjustment for mild-to-moderate renal impairment, an advantage shared across the GLP-1 class. The FDA product label for Wegovy confirms semaglutide 2.4 mg targets chronic weight management in adults with obesity or overweight with comorbidities.

FDA Approval Status

The approval status gap is the most clinically consequential difference between the two drugs.

Wegovy received FDA approval in June 2021 specifically for chronic weight management. Trulicity received FDA approval in 2014 for type 2 diabetes glycemic control, with a subsequent cardiovascular risk-reduction indication added based on REWIND trial data. Trulicity has never been approved for obesity treatment. Prescribing it off-label for weight loss means patients lack the insurance coverage pathway, the titration schedule, and the trial-backed dosing that Wegovy provides.

Dosing Schedules

Wegovy follows a five-step titration: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and the target maintenance dose of 2.4 mg from week 17 onward. Trulicity starts at 0.75 mg and can be escalated to 1.5 mg, 3.0 mg, or 4.5 mg for diabetes management. That upper ceiling of 4.5 mg still delivers less semaglutide-equivalent receptor activation than 2.4 mg semaglutide achieves.

Weight Loss: What the Trial Data Show

Weight loss is where the clinical gap between these two agents is most stark. The STEP program established Wegovy as the most effective non-surgical obesity pharmacotherapy available at the time of its approval. Dulaglutide trials show meaningful but far more modest body-weight reductions.

STEP-1 Trial Results for Wegovy

In STEP-1 (N=1,961), participants without diabetes who received semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% in the placebo group (P<0.001). That result, published in the New England Journal of Medicine in 2021, represents the largest placebo-controlled weight-loss outcome ever recorded for a non-surgical intervention at the time. Nearly 70% of participants on semaglutide achieved at least 10% weight loss, and 50.5% achieved at least 15%.

Dulaglutide Weight Loss Data

Dulaglutide trials used for diabetes approval reported weight changes of approximately 1 to 3 kg at standard doses. The AWARD-11 trial, which tested the higher 3.0 mg and 4.5 mg dulaglutide doses in people with type 2 diabetes, showed weight reductions of about 4.5 kg at 4.5 mg over 36 weeks. AWARD-11 data published in Diabetes Care confirm that even at the highest approved dulaglutide dose, weight loss is substantially less than semaglutide 2.4 mg achieves.

That translates, roughly, to a 3 to 5% body weight reduction versus Wegovy's 14.9%. For a 250-pound patient, the difference is about 25 pounds vs. 8 pounds over a similar timeframe.

Head-to-Head Indirect Comparisons

No randomized head-to-head trial has directly compared semaglutide 2.4 mg to dulaglutide for weight management. Network meta-analyses consistently rank once-weekly semaglutide at the top of the GLP-1 class for weight reduction. A 2022 network meta-analysis in Obesity Reviews (N across trials = 50,000+) found semaglutide 2.4 mg superior to all other GLP-1 agonists, including dulaglutide, for percentage body-weight reduction. Indirect comparisons carry methodological limitations, but the magnitude of difference is large enough that it is unlikely to disappear with direct trial data.

Cardiovascular Outcomes: Both Have Evidence, With Different Patient Populations

REWIND Trial (Dulaglutide)

The REWIND trial enrolled 9,901 adults with type 2 diabetes who had either established cardiovascular disease or multiple cardiovascular risk factors. At a median follow-up of 5.4 years, dulaglutide 1.5 mg reduced the composite of major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, cardiovascular death) by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99). REWIND, published in The Lancet in 2019, is notable because about 31% of enrollees had no prior CV event, making it the most primary-prevention-inclusive CVOT in the GLP-1 class at the time.

The absolute risk reduction was modest: 2.4 percentage points over 5.4 years. Dulaglutide's CV indication applies only in the context of type 2 diabetes.

SELECT Trial (Semaglutide)

The SELECT trial (N=17,604) tested semaglutide 2.4 mg specifically in adults with established cardiovascular disease who did NOT have diabetes. Over a mean follow-up of 39.8 months, semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). SELECT data published in the New England Journal of Medicine in 2023 led to the FDA adding a cardiovascular risk-reduction indication to Wegovy's label in March 2024. This is the first time any obesity medication has received a dedicated CV outcomes indication.

For patients with obesity and established atherosclerotic cardiovascular disease but without diabetes, Wegovy now has both an obesity indication and a CV outcomes indication. Trulicity has neither of those in that population.

Comparing the CV Evidence

The two drugs' cardiovascular trial results are not directly comparable because the populations differ fundamentally. REWIND enrolled people with diabetes; SELECT enrolled people without diabetes. Both showed benefit, but the clinical application differs:

• Trulicity for CV risk reduction requires a type 2 diabetes diagnosis.
• Wegovy for CV risk reduction applies to non-diabetic patients with established CVD and obesity or overweight.

Glycemic Control: Trulicity Has the Edge for Diabetes

Trulicity is a diabetes drug first. Its glycemic efficacy is well-established. Across the AWARD trials, dulaglutide at 1.5 mg reduced HbA1c by approximately 1.1 to 1.4 percentage points from baseline. At the higher 4.5 mg dose in AWARD-11, reductions approached 1.7 to 2.0 percentage points. FDA-approved dulaglutide labeling documents HbA1c reductions across multiple AWARD trials.

Wegovy (semaglutide 2.4 mg) also reduces HbA1c in people with type 2 diabetes. STEP-2 enrolled adults with type 2 diabetes and showed a 1.6 percentage point HbA1c reduction at 68 weeks. STEP-2 data are published in The Lancet. For someone who needs both weight management and glycemic control, Ozempic (semaglutide 1.0 to 2.0 mg, the diabetes-indication version) rather than Wegovy may be the more appropriate and insurance-accessible choice. But if weight is the primary clinical problem, Wegovy's 2.4 mg dose delivers more of both.

Side Effects and Tolerability

Shared GI Side Effects

Both drugs produce the GLP-1 class-typical gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are most common during the titration phase and generally improve with time. In STEP-1, nausea occurred in 44.2% of semaglutide patients vs. 16.0% of placebo patients. Discontinuation due to GI events occurred in 4.5% of the semaglutide group. Full tolerability data from STEP-1 are available in the NEJM publication. Dulaglutide's AWARD-11 trial reported nausea in approximately 18 to 22% of participants at the 4.5 mg dose.

Injection Site and Pen Device

Both drugs use pre-filled autoinjectors. Wegovy is injected subcutaneously in the abdomen, thigh, or upper arm once weekly. Trulicity uses a similar injection schedule. The Trulicity pen has a single-use, enclosed needle design some patients find easier. Wegovy pens require proper refrigeration and use within 28 days of first use. Neither device has a clinically meaningful tolerability advantage over the other.

Pancreatitis and Thyroid Risk

Both drugs carry class-level warnings for pancreatitis and the theoretical risk of thyroid C-cell tumors seen in rodent studies. Neither drug is recommended in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The FDA labels for both drugs carry identical black-box warnings on this point. Real-world pharmacovigilance data have not confirmed a clinically elevated thyroid cancer risk in humans at current approved doses, but the contraindication stands.

Real-World Evidence: What Post-Market Data Show

Semaglutide Real-World Weight Loss

A 2022 retrospective cohort study using US insurance claims data (N=3,541 patients starting semaglutide for weight management) found mean weight loss of approximately 10.9% at 12 months in patients who maintained treatment. Adherence was the main driver of outcome variability. Real-world semaglutide weight-loss data have been published in Obesity. Patients who discontinued before month 6 lost substantially less weight, underscoring the importance of continued therapy.

Dulaglutide Real-World Use

Real-world dulaglutide data come largely from diabetes registries. A 2021 analysis of US EMR data found that patients on dulaglutide 1.5 mg achieved HbA1c reductions of about 0.9 to 1.1 percentage points at 6 months, with weight changes of roughly 1.5 to 2.5 kg. These are consistent with trial results, if slightly attenuated, which is typical for real-world vs. Controlled-trial settings.

Adherence Patterns

Adherence to weekly GLP-1 injections at 12 months is generally 50 to 65% across real-world studies. Cost is the primary driver of discontinuation for Wegovy. Trulicity has broader generic manufacturer competition pressure coming, though biosimilar approvals have been slow in the GLP-1 space. The FDA's biosimilar approval tracker documents the current approval status of GLP-1 biosimilars.

The HealthRX clinical team has developed the following decision framework for providers choosing between Wegovy and Trulicity based on primary patient goals:

| Primary Goal | Best First Choice | Rationale | |---|---|---| | Weight loss only (no diabetes) | Wegovy | FDA-approved indication; 14.9% mean weight loss in STEP-1 | | Type 2 diabetes + modest weight loss | Trulicity or Ozempic | Diabetes approval; Trulicity has 5+ years CV data in T2D | | T2D + aggressive weight loss | Ozempic then consider Wegovy | Ozempic covers diabetes; Wegovy adds more weight-loss potency | | CVD without diabetes, obesity present | Wegovy | SELECT trial; dedicated CV + obesity indications | | CVD with diabetes | Trulicity or Ozempic | REWIND covers T2D+CVD population |

Switching from Wegovy to Trulicity: Should You Do It?

Switching from Wegovy to Trulicity almost always results in less weight loss. This is the most common clinical scenario patients ask about, usually driven by cost or insurance coverage changes.

What to Expect When Switching

Patients who switch from semaglutide 2.4 mg to dulaglutide should expect some weight regain. The STEP-4 trial (N=803) demonstrated this principle indirectly: participants who were switched from semaglutide to placebo after 20 weeks of treatment regained about two-thirds of lost weight by week 68. STEP-4 data are available in JAMA. Switching to dulaglutide rather than placebo would blunt but not eliminate that regain.

Clinically, a reasonable expectation is that a patient who lost 15% body weight on Wegovy may stabilize at 8 to 10% weight loss below their original baseline on dulaglutide, depending on dose and adherence.

How to Switch Safely

No pharmacokinetic washout is required between GLP-1 agents because there is no drug interaction risk. The standard approach is to administer the first dulaglutide dose the week after the last Wegovy dose. Starting dulaglutide at 0.75 mg and titrating as tolerated is recommended. GI side effects may recur briefly during the transition. Patients should be counseled that weight regain is likely and that the switch is a clinical compromise, not an equivalent substitution.

The Endocrine Society's 2023 obesity pharmacotherapy guidelines note that sustained therapy is necessary to maintain weight-loss outcomes and that discontinuation of effective therapy typically leads to weight regain. "Pharmacological therapy for obesity should be continued long-term," the Endocrine Society states in its 2023 Clinical Practice Guideline for Obesity Pharmacotherapy.

Insurance and Cost Considerations

Wegovy's list price is approximately $1,349/month without insurance. Manufacturer copay cards (Novo Nordisk WeGoTogether program) can reduce this to as low as $25/month for eligible commercially insured patients. Trulicity's list price is approximately $800, $900/month without insurance. Neither has a generic equivalent currently available in the United States. Medicare Part D coverage of Wegovy for obesity was restricted until the Inflation Reduction Act provisions began changing coverage landscapes, though cardiovascular indication coverage may now open additional pathways for eligible patients.

Who Should Choose Wegovy?

Wegovy is the appropriate choice for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. It is also appropriate for non-diabetic patients with established cardiovascular disease following the SELECT trial data and the updated FDA label. Patients who need the most weight loss, who want an FDA-approved obesity treatment, and who can access the medication through insurance or the manufacturer savings program should choose Wegovy over Trulicity.

Who Should Choose Trulicity?

Trulicity is appropriate for adults with type 2 diabetes who need glycemic control and cardiovascular risk reduction, particularly those who cannot access or tolerate semaglutide. It is also a reasonable option when weight loss is a secondary rather than primary goal. Patients for whom the 4.5 mg maximum dose is adequate for HbA1c management and who have established CVD can point to REWIND's 5.4-year follow-up data as supporting evidence.

Trulicity should not be chosen primarily for weight management. Its weight-loss outcomes, even at the highest approved dose, fall well short of what Wegovy delivers. The Obesity Medicine Association's position statement emphasizes that obesity requires treatment with agents approved and studied for that purpose, not off-label use of diabetes medications when effective approved options exist.